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Abstract
Myasthenia Gravis (MG) patients suffer from chronic fatigue of skeletal muscles, even after initiation of proper
immunosuppressive medication. Since the localization of neuronal nitric oxide synthase (nNOS) at the muscle membrane is
important for sustained muscle contraction, we here study the localization of nNOS in muscles from mice with acetylcholine
receptor antibody seropositive (AChR+) experimental autoimmune MG (EAMG). EAMG was induced in 8 week-old male
mice by immunization with AChRs purified from torpedo californica. Sham-injected wild type mice and mdx mice, a model
for Duchenne muscular dystrophy, were used for comparison. At EAMG disease grade 3 (severe myasthenic weakness), the
triceps, sternomastoid and masseter muscles were collected for analysis. Unlike in mdx muscles, total nNOS expression as
well as the presence of its binding partner syntrophin a-1, were not altered in EAMG. Immunohistological and biochemical
analysis showed that nNOS was lost from the muscle membrane and accumulated in the cytosol, which is likely the
consequence of blocked neuromuscular transmission. Atrophy of all examined EAMG muscles were supported by up-
regulated transcript levels of the atrogenes atrogin-1 and MuRF1, as well as MuRF1 protein, in combination with reduced
muscle fiber diameters. We propose that loss of sarcolemmal nNOS provides an additional mechanism for the chronic
muscle fatigue and secondary muscle atrophy in EAMG and MG.
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Introduction
Myasthenia Gravis (MG) is an autoimmune disorder where
autoantibodies target the nicotinic acetylcholine receptors (AChR)
at the neuromuscular junction (NMJ) in about 85% of patients [1].
These antibodies cause impaired neuromuscular transmission,
resulting in the cardinal symptoms of fluctuating skeletal muscle
weakness of predominantly proximal muscles in the face, neck,
arms and legs. Treatment consists of immunosuppressive medica-
tion along with symptomatic treatment, including acetylcholines-
terase inhibitors (AChEI), which renders the neurotransmitter
ACh available for longer time at the NMJ and thus temporarily
improves the neuromuscular transmission. Due to the beneficial
effects of the b2 adrenergic receptor (b2AR) agonist terbutaline on
muscle fatigue in MG patients, this drug has been used as
symptomatic treatment in a few neurology clinics [2,3](Punga AR,
unpublished observations). b2ARs are G protein coupled recep-
tors, and stimulation by b2AR agonists such as salbutamol
increases inctracellular levels of cyclic AMP and activates the
cyclic guanosine monophosphate (cGMP) pathway [4–6].
Nitric oxide (NO) is a signaling molecule involved in vital
physiological processes, such as neurotransmission and gene
regulation, by increasing intracellular levels of cGMP. In turn,
cGMP is inactivated by phosphodiesterases (PDEs), multi-domain
proteins with distinct catalytic and regulatory sites. The rat model
of EAMG is characterized by an increase of PDE subtypes in both
lymph nodes and in muscles [7]. Pentoxifylline, a general PDE
inhibitor, inhibits the progression of rat EAMG, suggesting the
involvement of PDE regulation in EAMG pathogenesis [7].
Additional studies have shown the up-regulation of PDE also in
human MG, but also in other autoimmune disorders such as
multiple sclerosis [8]. NO synthase (NOS) catalyzes the production
of NO and is present in three different isoforms: 1) neuronal NOS
(nNOS), expressed in for example motor neurons, skeletal and
smooth muscles 2) inducible NOS (iNOS), expressed in most cells
after immunological or inflammatory stimuli and 3) endothelial
NOS (eNOS), expressed in the endothelium. The neuronal form
nNOS is also expressed in fast-twitch fibers of skeletal muscles and
localizes to the cytosolic surface of the sarcolemma, where it binds
to syntrophin a-1, a component of the dystrophin-glycoprotein
complex. Upon muscle contraction, nNOS is stimulated to induce
vasodilatation through regulation of the local blood flow in the
muscle and thus increases blood supply of active muscles [9]. The
localization of nNOS at the sarcolemma is essential for instant
diffusion of NO to muscle vasculature where it induces vessel
dilatation via the cGMP pathway [10,11]. Denervation has been
reported to cause dissociation of nNOS from the sarcolemma,
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resulting in muscle fatigue due to absence of nNOS-cGMP
signaling [12–15]. Moreover, dissociation of nNOS from the
sarcolemma increases the NO availability in the cytosol, which in
turn causes up-regulation of the atrophy-inducing atrogenes
MuRF1 and atrogin-1 [15]. In the mdx mice, representing a model
of Duchenne muscular dystrophy, nNOS and its binding partner
syntrophin a-1 are absent from the sarcolemma due to failure of
assembly of the entire dystrophin-glycoprotein-complex [16].
One of the puzzling questions is why the majority of MG
patients continue to have chronic fatigue despite proper immu-
nosuppressive medication that should remove the circulating
autoantibodies and inhibit the T-and B-cell response. MG is
generally regarded as a disorder with no pathologic alterations of
the muscle fiber metabolism, although muscle atrophy, especially
of type II fibers, is known to arise in a large proportion of MG
patients [17–19]. Hence, additional mechanisms are suspected to
play a role.
In this work, we investigated the possibility of an alternative
pathway/mechanism, other than blocked neuromuscular trans-
mission, to explain the occurrence of post-exercise fatigue in
skeletal muscles in many MG patients on proper immunosup-
pressive therapy. We show that nNOS was lost from the muscle
membrane and accumulated in the cytosol of muscle fibers from
mice with AChR+ EAMG. Notably, the atrophy-related atrogenes
MuRF1 and atrogin-1 as well as the denervation marker AChRc
were highly up-regulated in all the muscles examined, which has
not previously been reported in EAMG with AChR antibodies.
Our data thus provide evidence for an additional mechanism that
might be involved in muscle fatigue and atrophy observed in
EAMG mice and in a large fraction of MG patients.
Methods
Experimental Animals
Wild type C57BL6 mice and dystrophic mdx mice [20] were
originally supplied from Jackson Laboratories (Bar Harbor,
Maine, US). For immunization, 8 week-old male C57BL6 mice
and 3 month-old male dystrophic mdx mice were used. All mice
were housed in the Animal Facility of Biozentrum, University of
Basel, where they had free access to food and water in a room with
controlled temperature and a 12-hour alternating light–dark cycle.
All animal procedures complied with Swiss animal experimental
regulations (ethical application approval no. 2352) and EC
Directive 86/609/EEC.
Immunization of Mice with AChR from Torpedo
Californica
AChRs were purified from the electric organs of torpedo californica
using cobratoxin affinity columns as described previously [21] and
were tested for integrity by SDS-PAGE. 18 C57BL6 male mice
aged 8 weeks were anesthetized (Ketamine: 111 mg/kg and
Xylazine: 22 mg/kg) and immunized with 20 mg of AChR
emulsified in complete Freund’s adjuvant (CFA, Difco laborato-
ries) subcutaneously in the hind foot pads, at the base of the tail
and dorsolateral on the back. At day 28 post-injection, immuni-
zation was repeated. Control mice (5 male mice) were immunized
with PBS/CFA at day 0 and day 28 (similar to the EAMG
immunization protocol).
Clinical Examination
Body weight was monitored weekly. Mice were provided with
soft, wet food in the cage to minimize the contribution of
insufficient food and water intake to the body weight loss. Muscle
fatigue/weakness of the immunized mice was assessed once a week,
as previously described [22]. Briefly, mice were exercised by 20
consecutive front and hind paw grips on a vertical grid, gently held
at the base of their tail. The mice were then placed on an upside-
down grid. The time they could hold on to the grid reflected the
grade of fatigue and muscle weakness. EAMG grades were as
follows: Grade 0, no fatigue (.150 sec), normal posture; Grade 1,
mild muscle fatigue after exercise (,60 sec), normal posture;
Grade 2, moderate muscle fatigue (,30 sec), change to hunched
posture with body weight loss and decreased activity; Grade 3,
severe generalized weakness (,0 sec), generalized weakness,
hunched posture with flaccid paralysis, obvious loss of body
weight, moribund. The following muscles were obtained from
mice with EAMG grade 3 (n= 8): triceps, masseter and
sternomastoid muscles. Repetitive nerve stimulation of the sciatic
nerve was done as previously described [23].
ELISA
Sera were obtained from tail vein blood at the day of dissection
(day 35 to 49 post-immunization). ELISA plates (Nunc MaxiSorp,
Fisher Thermo Scientific) were coated with 50 ml/well of
recombinant purified AChRs (8 ng/ml), blocked with 3% BSA/
PBS and then incubated with a sera dilution row (1:3000–
1:6561,000). After washing, plates were incubated with secondary
HRP-conjugated goat-anti-mouse (1:2000; Jackson Immuno Re-
search Laboratories). HRP was activated by a TMB substrate and
the reaction was stopped with 1N HCl. Absorbance was read at
450 nm. Sera from CFA/PBS injected mice constituted negative
controls and monoclonal mouse anti-AChR a subunit antibody;
mAb35 [24] served as positive control.
Quantitative PCR Analysis
Mouse muscle RNA was extracted and purified as previously
described [23]. Equal amounts of total RNA were used for cDNA
synthesis (iScript cDNA Synthesis Kit, BioRad). RT-PCR
reactions (triplicates) were performed using Power SYBR Green
PCR Master Mix reagent (Applied Biosystems, Warrington, UK).
b-actin served as endogenous control. The following primer sets
were used:
nNOS: 59-GGG CAA ACA GTC TCC TAC CA-39 and 59-
AGG GTG TCA GTG AGG ACC AC-39; atrogin-1:59-CTC
TGT ACC ATG CCG TTC CT-39 and 59-GGC TGC TGA
ACA GAT TCT CC-39; MuRF1:59-ACC TGC TGG TGG AAA
ACA-39 and 59-AGG AGC AAG TAG GCA CCT CA-39;
AChR-c subunit: 59-AAC GAG ACT CGG ATG TGG TC-39
and 59-GTC GCA CCA CTG CAT CTC TA-39; b-actin: 9-CAG
CTT CTT TGC AGC TCC TT-39 and 59-GCA GCG ATA
TCG TCA TCC A-39.
Total Protein Extraction and Protein Fractionation
Triceps, masseter and sternomastoid muscles were pulverized
on a liquid nitrogen-cooled metal plate and total protein was
extracted by homogenization in RIPA buffer containing protease
inhibitors (Roche Diagnostics). The subcellular fractionation was
done as previously described [16]. In brief, pulverized muscles
were homogenized in 10 volumes (w/v) of buffer A (25 mM Tris–
HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA)
containing protease inhibitors (Roche Diagnostics) followed by
centrifugation at 10006g to pellet the nuclei. The supernatant was
then centrifuged at 20,0006g to yield the supernatant S1, referring
to the soluble fraction. The pellet from this centrifugation was
resuspended in buffer B (500 mM NaCl added to buffer A),
incubated for 30 min at 4uC with agitation and then centrifuged at
15,0006g for 30 min, yielding supernatant S2 (microsomal
membrane fraction). The pellet from this last centrifugation was
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further resuspended in buffer B, containing 0.5% Triton X-100,
incubated for 30 min at 4uC with agitation, and centrifuged at
15,0006g for 30 min to get supernatant S3 (cytoskeletal fraction)
and the final pellet, P (sarcolemma). The fractions were resolved
using the loading buffer (Laemmli) and analyzed by SDS-gel
electrophoresis.
Western Blot Analysis
Protein concentration of the total protein fraction, the soluble
fraction S1 and the sarcolemmal final pellet P was determined
using BCA Protein assay kit (PIERCE). Western blot of triceps,
masseter and sternomastoid muscles was conducted as described
[25]. 20 mg of total protein was resolved on a 4–12% Nu-PAGE
Bis-Tris gel (Invitrogen) and then transferred to nitrocellulose
membrane. Similarly, 20 mg of protein fraction from each muscle
was separated on a 6% Laemmli SDS-polyacrylamid gel and then
transferred to a nitrocellulose membrane. The membranes were
probed with rabbit polyclonal anti-nNOS (160 kD, 1:500,
Invitrogen 61–7000) and rabbit monoclonal anti-b-actin (45 kD,
1:1000, NEB) or with rabbit polyclonal anti-MuRF1/TRIM63
MaxPab (40 kD, 1:1000, Abnova D01) and rabbit polyclonal anti-
b-tubulin (55 kD, 1:500, Abcam ab6046). Bound antibodies were
then recognized with HRP-conjugated antibody (1:5000; ICL).
Chemiluminescence was performed using LumiGLO Chemilumi-
nescent Substrate System (KPL, 54-61-00). Quantification of band
densitometry was done in ImageJ, with normalization to the
reference b-actin or b-tubulin.
Immunostainings and H&E Staining
Muscles were snap-frozen in liquid nitrogen-cooled isopentane
(–150uC), embedded in 7% gum Tragacanth (Sigma) and cross-
sections of 12-mm thicknesses were cut. General histology was
performed using Hematoxylin & Eosin staining (H? Merck). The
antibodies used for immunofluorescence were purchased from the
following commercial sources: rabbit anti-nNOS (1:100, Invitro-
gen), rabbit anti-syntrophin a-1 (1:500, GeneTex GTX11187) and
rat anti-laminin-c1 B2 chain (1:500, Millipore MAB1914).
Membrane-bound and extracellular epitopes were visualized with
Alexa-488-conjugated wheat germ agglutinin (WGA; Molecular
Probes, Eugene, OR, USA). Secondary antibodies were Cy3-
conjugated donkey anti-rabbit (BioLegend, 406402) and Dy-Light
488 goat anti-rat (BioLegend, 405409). Pictures of stained,
consecutive cross-sections were collected using a Leica
DM5000B fluorescence microscope, a digital camera (F-View;
Soft Imaging System), and analySISH software (Soft Imaging
System).
Histological Quantifications
The percentage of fibers with cytosolic nNOS staining in
AChR+ EAMG muscles was evaluated by counting a total of 300
muscle fibers per section. The muscle fiber size distribution was
quantified on WGA-stained cross-sections using the minimum
distance of parallel tangents at opposing particle borders (minimal
‘‘Feret’s diameter’’) as described [26]. Normalization of the
number of fibers in each fiber Feret class of 5 mm was based on
the total fiber number measured per muscle.
Statistical Analysis
Quantitative data are expressed as mean 6 SEM. P-values were
calculated using the unpaired two-sample Student t-test assuming
equal variances and the significance level was defined as p,0.05.
Results
Fatigue and Weight Loss in AChR+ EAMG
AChRs were affinity-purified from the electric organ of torpedo
californica using cobratoxin-coupled Sepharose beads [21]. To test
for purity, eluates were analyzed by SDS-PAGE followed by
Figure 1. Immunization of mice with purified AChRs causes production of autoantibodies along with clinical and
neurophysiological signs of experimental autoimmune MG (EAMG). (A) The purification of AChRs from the electric organs of torpedo
californica contained the subunits of: d, c, b and a at their corresponding sizes. (B) The typical clinical presentation in AChR+ mice with EAMG disease
grade 3 was flaccid paralysis, with inability to rise up on the hind limbs, tail down and chin down (arrows). (C) The mice were examined with low
frequency (3 Hz) repetitive nerve stimulation of the sciatic nerve. A representative decrement, ‘‘run down’’ (arrows), of the compound motor action
potentials (CMAPs) of ,30% was noted between the 1st and 4th CMAP in the EAMG mice. A decrement exceeding 10% was considered pathological.
doi:10.1371/journal.pone.0044148.g001
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Coomassie-blue staining. All four AChR subunits (a,b,d,c) were
present at their expected sizes, while the last wash fractions of the
columns were free of any protein (Fig. 1A). Eighteen mice were
immunized with the purified AChRs in CFA. Out of these mice, 1
mouse (5%) unexpectedly died during the course of the
experiment, 5 mice (28%) did not develop any myasthenic
symptoms (grade 0), 3 mice (17%) developed mild fatigue upon
exercise (grade 1), 1 mouse (5%) reached EAMG disease grade 2
and the remaining 8 mice (45%) developed severe EAMG (grade
3) at various time points from 35 days up to 49 days. The
phenotype of EAMG grade 3 included severe myasthenic
weakness with hunched posture, flaccid paralysis and obvious
weight loss [27] (Fig. 1B). Impaired neuromuscular transmission
was confirmed by decrement of the compound motor action
potentials (CMAP) on in vivo repetitive sciatic nerve stimulation
(Fig. 1C). Disease severity progressed after the 2nd boost at day 28,
with weight loss (Fig. 2A) and muscle fatigue upon exercise on an
upside-down grid [22] (Fig. 2B). Both parameters correlated well
with the disease grade and could therefore be used to follow
disease progression in the EAMG mice. None of the control mice
(n = 5) displayed any weight loss or muscle fatigue (.150 s on the
grid). Immunized mice that developed obvious severe myasthenic
symptoms (n= 8) were sacrificed one to three weeks after the boost
(day 35 to day 49 post-immunization), when reaching EAMG
grade 3. In these mice, an elevated titer of AChR antibodies was
detected in the sera, which were collected at the day of
euthanization. AChR antibodies were present in sera from all
examined EAMG mice with severe myasthenic weakness and the
titers were higher than the titer measured from the positive control
(anti-AChR antibody mAb35; Fig. 2C).
Normal Transcript and Protein Levels of nNOS in Muscles
of EAMG Mice
Since triceps, masseter and sternomastoid muscles represent
proximal and facial muscles that are often affected by myasthenic
fatigue, these muscles were examined for their total mRNA and
protein levels of nNOS. Total nNOS transcript levels in muscles of
AChR+ EAMG mice with disease grade 3 were comparable to
those from muscles of healthy control mice injected with CFA/
PBS (ctrl; Fig. 3A). In contrast and as previously reported [28],
muscles from mdx mice, a model of Duchenne muscular dystrophy,
showed a strong reduction of nNOS mRNA expression (Fig. 3A).
Figure 2. Clinical characteristics of EAMG mice that developed a severe disease phenotype (EAMG grade 3; n=8). (A) Loss of body
weight in the AChR+ EAMG mice started after day 28. Day of dissection is indicated by a square (35, 42 or 49 days after post-immunization). (B) The
time AChR+ EAMG mice could hold on to the upside-down grid is displayed. Mice with a grid time ,0 seconds (EAMG grade 3) were sacrificed for
analysis. The day of dissection is indicated by a square. (C) ELISA analyzed the immunoreactivity of AChR autoantibodies in sera from immunized
mice. The background from negative controls was subtracted and anti-AChR antibody mAb35 was used as positive control. Half maximum titer is
indicated. Control mice (ctrl) were immunized with CFA/PBS.
doi:10.1371/journal.pone.0044148.g002
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Similar results were obtained by Western blot analysis in total
muscle protein extracts from the triceps, masseter and sternomas-
toid muscles. There, total protein levels of nNOS in AChR+
EAMG muscles were the same as in control muscles, but again
nNOS was significantly reduced in muscles from mdx mice
(Fig. 3B). Thus, the total amount of nNOS in AChR+ EAMG
muscles is comparable to control muscles, in contrast to the
strongly reduced nNOS levels in muscles from mdx mice.
nNOS is Lost from the Sarcolemma and Accumulates in
the Cytosol in EAMG
To examine the subcellular localization of nNOS in AChR+
EAMG mice, cross-sections of triceps (Fig. 4A), masseter (Fig. 4B)
and sternomastoid (Fig. 4C) muscles were stained for nNOS
(second row in each figure) and for the basement membrane
protein laminin-c1 (LN1 c; first panel). Whereas the sarcolemmal
staining for nNOS was strong in control mice, it was partially or
completely absent in some fibers of the muscles in AChR+ EAMG
mice (center panel in each of Fig. 4A, B, C). In addition, several
muscle fibers showed an increase in cytosolic staining for nNOS
(Fig. 4A, B, C), indicating loss of nNOS from the sarcolemma to
the cytosol in those fibers. In agreement with previous reports [16],
the amount of nNOS was strongly reduced in all examined
muscles from the mdx mice. To test whether nNOS was lost from
the sarcolemma in AChR+ EAMG mice because of displacement
of its binding partner syntrophin a-1, consecutive sections were
stained for syntrophin a1 (third row of panels in Fig. 4A, B, C). In
contrast to mdx muscles, where syntrophin a-1-immunoreactivity
was absent at the sarcolemma, syntrophin-a1 was still detected at
the sarcolemma of AChR+ EAMG muscles and its levels were
comparable to those from control muscles.
To obtain an estimate of the extent of nNOS that was lost from
the sarcolemma into the cytosol, the percentage of fibers with
cytosolic nNOS staining was counted in AChR+ EAMG muscles
(Fig. 4D). A clear cytosolic signal for nNOS could be detected in
10–11% of EAMG muscle fibers, whereas no fibers positive for
nNOS in the cytosol were found in control muscles or in muscles
from mdx mice.
To test whether nNOS that disappeared from the sarcolemma
could still be found in the cytosol, we next performed subcellular
fractionation of the muscle followed by Western blot analysis.
While the amount of nNOS was approximately the same in the
soluble (cytosol) and the membrane (sarcolemma) fraction in
control mice, the majority of nNOS was detected in the soluble
fraction in both AChR+ EAMG and mdx mice (Fig. 4E). These
results indicate that the connection of nNOS to the sarcolemma
becomes very fragile in AChR+ EAMG muscles and thus nNOS is
lost from the membrane and accumulates in the cytosol.
Functional Denervation and Muscle Atrophy Parallels the
Loss of Sarcolemmal nNOS in EAMG
Dissociation of sarcolemmal nNOS has previously been
reported in mice upon hind-limb suspension and denervation
[15]. To examine whether partial denervation may also induce
nNOS dissociation from the sarcolemma in AChR+ EAMG,
mRNA levels of the fetal AChRc subunit, a marker for blocked
neuromuscular transmission and denervation, were determined.
Indeed, AChRc was significantly up-regulated in AChR+ EAMG
muscles (Fig. 5A), suggesting that loss of sarcolemmal nNOS arises
from functional denervation, which could be mediated by the
AChR blocking autoantibodies. The up-regulation of AChRc in
muscle fibers of mdx mice was in support of previous studies of the
diaphragm and interosseus muscles [29,30].
Further, nNOS accumulation in the cytosol has been linked to
promotion of muscle atrophy by up-regulation of the E3 ligases
[15]. Indeed, mRNA levels of the two atrophy-associated genes
atrogin-1 (Fig. 5B) and MuRF1 (Fig. 5C) were highly up-regulated
in all examined EAMG muscles. Accordingly, MuRF1 protein
levels were also increased (Fig. 5D). In contrast, mRNA levels of
both atrogenes were rather reduced in mdx muscles (Fig. 5B–C),
which can be explained by the so-called ‘‘pseudohypertrophy’’ that
develops in the mdx mice as well as in patients with Duchenne
muscular dystrophy. Muscle fiber atrophy was visualized in H&E
Figure 3. Total transcript and protein levels of nNOS are normal in muscles of EAMG mice. (A) Total mRNA amount of nNOS in triceps,
masseter and sternomastoid muscles. Negative controls were muscles from healthy CFA/PBS injected control mice (ctrl; n = 3) and as positive control
muscles from mdx mice were used (mdx; n = 3). In the AChR+ EAMG muscles (AChR+; n = 6), total nNOS levels were unchanged as compared to
controls (triceps p = 0.55; triceps p= 0.32; triceps p = 0.90). nNOS mRNA was clearly reduced in mdx muscles. (B) Western blot analysis of nNOS
(160 kD) levels in total protein extracts from triceps (Trc), masseter (Mass) and sternomastoid (STM) muscles. Representative results are shown. No
difference was seen between nNOS protein content in AChR+ EAMG (AChR+; n = 3) and control (ctrl; n = 3) muscles, whereas nNOS protein was
reduced in muscles of mdx (mdx; n = 3)-mice to approximately 20%. b-actin was used as reference protein.
doi:10.1371/journal.pone.0044148.g003
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stained EAMG muscle cross-sections (Fig. 5E) and a quantitative
evaluation of the fiber size distribution confirmed the shift to
smaller fibers in AChR+ EAMG compared to control muscles
(Fig. 5F). In summary, denervation marker and atrophy factors
were up regulated and muscle fiber atrophy was evident in all
examined muscles of EAMG mice.
Figure 4. nNOS is lost from the sarcolemma and accumulates in the cytosol in muscles of EAMGmice. Immunostaining of cross-sections
from (A) triceps, (B) masseter and (C) sternomastoid muscles with laminin-c1 (LNc1; first panels), nNOS (second panels) and syntrophin-a1 (Syna1;
third panels) antibodies. Representative images are shown. In contrast to CFA/PBS injected control mice (ctrl; n = 3 for each muscle), sarcolemmal
nNOS staining partially disappeared from the sarcolemma and was instead present in the cytosol (arrows) in AChR+ EAMG muscles (AChR+; n = 4 for
each muscle). Syntrophin a-1, the binding partner of nNOS, stably remained at the membrane. nNOS and syntrophin a-1 both were almost absent in
mdx muscles (n = 2 for each muscle). Asterisks indicate identical fibers in consecutive sections. (D) 10–11% of the fibers in AChR+ EAMG muscles were
positive for cytosolic nNOS staining, whereas no such fiber was found in control muscles. (E) Western blot analysis of the nNOS protein levels present
in the soluble (cytosol; upper panel) and the membrane (sarcolemma; lower panel) protein fraction of triceps (Trc), masseter (Mass) and
sternomastoid (STM) muscles. Representative bands are shown. nNOS levels were increased in the soluble fraction of muscles from AChR+ EAMG
mice (AChR+; n = 6) with approximately 80% when compared to muscles from CFA/PBS injected control mice (ctrl; n = 4). In mdx mice (n = 3),
approximately 70% of nNOS protein remained in the cytosol. In the membrane fraction, indicating sarcolemmal position, nNOS was reduced to 30%
of control values in AChR+ EAMG mouse muscles and to 20% in mdx muscles. Scale bars = 50 mm.
doi:10.1371/journal.pone.0044148.g004
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Figure 5. Denervation and atrophy in triceps (Trc), masseter (Mass) and sternomastoid (STM) muscles of EAMGmice. (A) mRNA levels
of AChRc subunit, a marker for blocked neuromuscular transmission and denervation, were up-regulated 25–40 times (p,0.005 for all muscles) in
muscles of AChR+ EAMG mice (n = 6) when compared to controls (ctrl; n = 3). (B) mRNA levels of the atrophy-related gene atrogin-1 were 6.5–
Loss of Sarcolemmal nNOS in MG
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Discussion
The clinical hallmark of AChR+ MG patients, as well as
AChR+ EAMG mice, is a varying degree of fatigable weakness of
proximal skeletal muscles. Since many MG patients continue to
have post-exercise fatigue of skeletal muscles although proper
immunosuppressive treatment has been initiated, the question
arises of whether additional mechanisms contribute to atrophy or
blocked neuromuscular transmission.
Loss of nNOS from the sarcolemma is found in muscles from
patients with distinct myopathies and there is an association of
whole-body fatigue with loss of sarcolemmal nNOS in mice [12].
Although MG is generally regarded as a disorder with no
pathological alterations of the muscle fiber metabolism or
structure, the present findings of nNOS translocation from the
membrane to the cytosol in AChR+ EAMG mice, suggest
a common mechanism of fatigue in myasthenia and myopathies.
In fact, this mechanism is likely to contribute to the muscle fatigue
response to exercise, since sarcolemma-localized nNOS signaling
in skeletal muscle is required to maintain cGMP-mediated
vasodilation of contracting muscles [11].
b2AR agonists, mainly terbutaline, have been reported to
ameliorate the clinical symptoms in MG patients [3] and recently
this group of medication (albuterol) was recognized to improve
clinical symptoms also in patients with congenital myasthenic
syndromes (CMS) [31]. A randomized placebo-controlled pilot
study of terbutaline in MG patients showed a significant
improvement in clinical quantitative fatigue score as well as an
improvement in the fatigue response on repetitive nerve stimula-
tion [2]. Stimulation with salbutamol is known to result in an
accumulation of cGMP in the arterial mesenteric bed, indicating
that activation of b2-ARs is coupled to the stimulation of cGMP
production by the arterial mesenteric bed along with increased
NO release [4,5]. Hence, b2-AR agonist-induced vasodilatation
7.5 times increased in AChR+ EAMG (n= 6) compared to control (ctrl; n = 3; p,0.005 for all muscles). (C) mRNA levels of the atrophy inducing gene
MuRF1 were around 8 times higher in AChR+ EAMG (n= 6) compared to control (ctrl; n = 3; p,0.005 for all muscles). In mdx muscles (n = 3) atrogin-1
and MuRF1 mRNA was down-regulated compared to control mice. (D) Western blot analysis shows increased MuRF1 protein levels in AChR+ EAMG
muscles. b-tubulin (b-tub) was used as loading control. (E) H&E staining visualizes smaller atrophied fibers in AChR+ EAMG than in control muscles. (F)
Muscle fiber size distribution shifts for 5 to 15 mm to smaller fibers in AChR+ EAMG muscles, indicating atrophy (N= 4). Values represent relative
numbers of fibers in a given diameter class (5 mm/class).
doi:10.1371/journal.pone.0044148.g005
Figure 6. Proposed model of translocation of sarcolemmal nNOS to the cytosol and its consequences in EAMG. In normal muscle
fibers, where nNOS is present at the sarcolemma, localized NO production at the membrane is essential for sustained muscle contraction through
activation of cyclic GMP. Antibodies (IgG1) against the nicotinic acetylcholine receptors (AChRs) at the muscle membrane cause impaired
neuromuscular transmission and functional denervation of some muscle fibers. The consequential dissociation of nNOS from its binding partner
syntrophin-a1 to the cytosol causes an up-regulation of atrogene transcription (MuRF1 and atrogin-1). Lack of sarcolemmal nNOS signaling is
believed to contribute to muscle fatigue by impeding cGMP-mediated vasodilatation, while the atrogene up-regulation in turn is believed to cause
secondary muscle atrophy.
doi:10.1371/journal.pone.0044148.g006
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could provide a basis for improvement of fatigue in MG patients,
through increasing blood flow to the skeletal muscles by enhancing
NO-cGMP signaling. In the rat model of EAMG, several PDE
subtypes were up regulated both in the lymph nodes and in the
muscles and the general PDE inhibitor pentoxifylline inhibited the
progression of EAMG [7,8]. Hence, since inhibition of PDE
increases the amount of intracellular cGMP this could explain why
less muscle involvement is found in EAMG rats upon this
treatment [7].
After denervation of adult muscles the embryonic-type AChRs,
AChRc, are again expressed over the entire fiber length and
disappear upon reinnervation [32]. Our data indicate a denerva-
tion process in AChR+ EAMG mice. Up-regulation of the
embryonic AChRs has previously been reported in fibers from
both the interosseus and diaphragm muscles in mdx mice, similar
to our findings, indicating a denervation/regeneration process of
the dystrophin-deficient muscle fibers [29,30]. Since dissociation of
nNOS from the sarcolemma can be induced by denervation or
‘‘muscle unloading’’ [15], the up-regulation of the denervation
marker AChRc indicates that the weak connection of nNOS to
the sarcolemma in AChR+ EAMG mice may arise from impaired
neuromuscular transmission caused by the antibody-mediated
blockade of AChRs. Further, we provide evidence that in contrast
to mdx muscles, in which both nNOS and its binding partner
syntrophin-a1 are absent from the sarcolemma due to failure of
assembly of the entire dystrophin-glycoprotein-complex, syntro-
phin-a1 deficiency is not the reason for nNOS loss at the
sarcolemma in EAMG mice.
Mice deficient for nNOS appear normal regarding activity,
breeding and memory [33] and no muscle pathology nor loss of
muscle force has been observed [12]. Nevertheless, nNOS
knockout mice display a deficit in their adaptation to exercise
and thus experience muscle fatigue [14]. However, the low levels
of nNOS in mdx mice both at the mRNA and the protein level in
whole muscle extracts were in contrast to the AChR+ EAMG
mice, where the reduced sarcolemmal nNOS was seen in parallel
with a significantly increased cytosolic nNOS level. As reported in
other neuromuscular diseases such as amyotrophic lateral sclerosis
[34], an excess of NO production in the cytosol boosts muscle
atrophy through action on the atrogenes Foxo3a, MuRF1 and
atrogin-1 [15]. The significant up-regulation of these atrophy
markers have previously been described only in facial muscles of
EAMG mice with antibodies against muscle specific tyrosine
kinase (MuSK), however our data indicate that muscle atrophy
occurs at an early stage also in AChR+ EAMG. This in turn most
likely causes a ‘‘vicious circle’’, where the presence of cytosolic
nNOS causes activation of the E3 ligases [15], resulting in
aggravated atrophy and chronic fatigue (Fig. 6). The AChR+
EAMG model is naturally more dramatic than the typical gradual
onset of MG in human patients, which could in part explain the
strong up-regulation of the atrogenes MuRF1 and atrogin-1 as
well as the denervation marker AChRc. Notwithstanding, type II
fiber atrophy has been recognized in a large proportion of MG
patients [19] and this is often referred to as ‘‘disuse atrophy’’.
In summary, we show that nNOS is lost from the sarcolemma
and accumulates in the cytosol in muscle fibers of EAMG mice.
Absence of sarcolemmal nNOS represents a possible mechanism
for the chronic fatigue experienced by AChR+ MG patients. In
addition, increased nNOS availability in the cytosol provides
a potential explanation for the muscle atrophy in patients with
long-term severe MG weakness.
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